<DOC>
	<DOCNO>NCT00002912</DOCNO>
	<brief_summary>Phase I trial study effectiveness PSC-833 plus etoposide mitoxantrone treat child refractory relapse acute leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Some cancer become resistant chemotherapy drug . Combining PSC-833 chemotherapy may reduce resistance drug allow cancer cell kill .</brief_summary>
	<brief_title>Combination Chemotherapy Plus PSC-833 Treating Children With Refractory Relapsed Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose PSC-833 combination mitoxantrone etoposide child refractory relapse acute leukemia . II . Determine effect PSC-833 mitoxantrone etoposide pharmacokinetics . III . Quantify MDR1 gene expression MDR1 P-glycoprotein expression function patient-derived leukemia cell . OUTLINE : This dose escalation study PSC-833 . Patients undergo induction therapy consist etoposide IV mitoxantrone IV day 1-5 . Patients receive PSC-833 IV 124 hour begin day 2 . A second course administer sooner 21 day start first course marrow hypocellular first course . Patients persistent disease 2 induction course remove study . Patients receive total 3 course etoposide/mitoxantrone . Patients achieve complete remission 1 induction course receive 2 course etoposide/mitoxantrone PSC-833 consolidation , begin within 4 week attainment complete remission . Patients achieve complete remission 2 induction course receive 1 course etoposide/mitoxantrone PSC-833 consolidation . Cohorts 3-6 patient receive escalate dos PSC-833 maximum tolerate dose determine . Patients follow every 6 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myeloid leukemia ( AML ) one follow category : First relapse initial CR le 6 month Refractory first second induction daunomycin , cytarabine , thioguanine ( DAT ) anthracyclinecontaining regimen Relapse follow bone marrow transplantation provide good trilineage engraftment follow transplant great 6 month since transplant Presentation secondary AML AML evolve myelodysplastic syndrome Acute lymphocytic leukemia one follow category : In second subsequent relapse fail second late induction attempt regardless prior remission Relapsed follow bone marrow transplantation provide good trilineage engraftment follow transplant great 6 month since transplant No isolate CNS extramedullary relapse PATIENT CHARACTERISTICS : Age : Under 22 diagnosis Performance status : Karnofsky 50100 % ( ECOG 02 ) Lansky 40100 % ( patient 12 year age ) Life expectancy : At least 8 week Bilirubin le 1.5 mg/dL ALT le twice normal Creatinine normal age ( within 2 standard deviation ) OR glomular filtration rate least 70 mL/min Albumin least 3 g/dL Ejection fraction great 50 % rest 5 % increase exercise OR shorten fraction great 27 % echocardiogram No history clinical heart failure No uncontrolled infection No anticonvulsant therapy No history allergic reaction anaphylaxis etoposide remediable premedication Not pregnant nursing Fertile patient must use effective contraception Third percentile weight height PRIOR CONCURRENT THERAPY : At least 4 week since chemotherapy recover Prior cumulative anthracycline dose great 360 mg per square meter Hydroxyurea therapy allow prior study rapidly rise blast count</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>